ATHN, ORFG, REGN, NHPR, PDLI - CRWEWallstreet.com Stock Report! February 21st 2011

Orofino Gold Corp. (ORFG.PK)'s mission is to become a 100,000 ounce gold producer from their first mine and to replicate this on each of the current optioned properties.
By: Hanson
 
Feb. 21, 2011 - PRLog -- Athenahealth, Inc.  announced the appointment of Stephen N. Kahane, MD, MS as President of the Company’s Enterprise Services Group. This is a new position created to accelerate the adoption of athenahealth’s cloud-based services in the critical enterprise and large hospital segment. Dr. Kahane will report directly to athenahealth CEO and Chairman, Jonathan Bush. Dr. Kahane brings more than 30 years of experience on the front lines of care, as well as driving growth and profitability for a number of healthcare IT businesses.

athenahealth, Inc. engages in the provision of Internet-based business services for physician practices primarily in the United States.





Orofino Gold Corp. (ORFG.PK)'s mission is to become a 100,000 ounce gold producer from their first mine and to replicate this on each of the current optioned properties.

The vision of Orofino Gold Corp.:

   * To become a good Joint Venture Partner
   * To become a premier Mid Tier precious metals mining operation in Colombia
   * To fast track their first mine to commercial production.

ORFG has announced the appointment of Mr. Salvador Rivero to the company's Board of Directors.

Mr. Rivero brings to Orofino a wealth of knowledge in the areas of business, corporate finance, and mining operations. After graduating from law school in Mexico, Mr. Rivero spent the next 25 years developing a thorough understanding of the processes necessary to successfully discover, acquire, and develop, mineral concessions with the potential of containing valuable mineral deposits. Considered by Orofino as an acquisitions specialist, Mr. Rivero has been involved in the development of various turn-key projects in mining, energy, fertilizer, oil and gas, and shipping sectors.

More about ORFG at:www.orofinogold.com



Regeneron Pharmaceuticals, Inc  announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones. "2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States.





Now we all know that the uninsured pay more for care-and have less-than those with insurance. However when the uninsured can not pay, health care providers adjust those costs to the who can pay-those which passes the buck to those who have insurance policy. This then leads to higher costs for those who buy the insurance on the particular market, as well as individuals who get insurance coverage for themselves and their own families through their job. The need for affordable healthcare alternatives has never been greater.

National Health Partners, Inc. (National Health) (OTCBB-NHPR.OB), a leading provider of unique discount healthcare membership programs, announced that the Company has achieved positive earnings for the quarter ended September 30, 2010 compared to a loss of $522,542 for the same period last year. Revenues for the 3rd quarter grew 12.3% over the same period last year. The Company attributes the net earnings to the significant cost-cutting initiatives taken over the past couple of quarters and which is continuing in the 4th quarter.

National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.”

More about NHPR at: www.nationalhealthpartners.com



PDL BioPharma, Inc.  announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis® and PDL's patents known as the Queen et al. patents. Under the settlement agreement, PDL paid MedImmune $65 million on February 15, 2011 and will pay $27.5 million by February 10, 2012 for a total of $92.5 million. MedImmune has not paid royalties to PDL on sales of Synagis that occurred after September 30, 2009. No further payments will be owed by MedImmune to PDL under its license to the Queen et al. patents as a result of past or future Synagis sales.

PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies.




Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(Read more at http://crwewallstreet.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising. Crown Equity Holdings Inc. (CRWE.OB) has received 3,000,000 shares of (144) restricted common stock from the company and anticipates receiving 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (NHPR.OB).
End
Source:Hanson
Email:***@crwewallstreet.com Email Verified
Tags:Aetna, Ary Fernando Pernett, Carexpress, David Daniels, Discount Healthcare Membership Programs, Gold Mine, La Azul
Industry:Business, Financial, Marketing
Account Email Address Verified     Disclaimer     Report Abuse
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share